Dako enters collaboration with Genentech on diagnostic tests for patients with stomach cancer

13-Aug-2009 - USA

Dako has signed an agreement with Genentech, Inc. to collaborate on the regulatory submissions of Dako's HercepTest(TM) and HER2 FISH pharmDx(TM) as companion diagnostics for Herceptin® (trastuzumab) in patients with advanced HER2-positive stomach (gastric) cancer.

The collaboration involves the use of Dako's extensive experience in developing cancer diagnostic tests to identify cancer patients who may receive greater benefits from a certain therapy.

Under the terms of the agreement, Dako and Genentech will collaborate on regulatory submissions for HercepTest(TM) and HER2 FISH pharmDx(TM) in the U.S. market to identify patients with stomach cancer who may be eligible for treatment with Herceptin if Herceptin is approved for use against that disease.

Based on the Herceptin ToGA Phase III study results, which were presented at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida, Genentech may seek regulatory approvals in the U.S. for the use of Herceptin in advanced HER2-positive stomach cancer.

"Herceptin and Dako's companion diagnostics HercepTest(TM) and HER2 FISH pharmDx(TM) have brought significant benefit to women with HER2-positive breast cancer. We are very excited to work with Genentech to extend these successful companion diagnostics to patients with stomach cancer," says Lars Holmkvist, CEO and President of the Dako Group.

The collaboration is in line with Dako's ongoing strategy to combine its strengths with biotechnology and pharmaceutical companies to develop the offering of Dako's companion diagnostic assays.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures